Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases

Abstract

Amgen disclosed a series of 4-heteroaryloxy quinoline/quinazoline compounds as multiple kinase inhibitors, including hepatocyte growth factor (HGF) receptor tyrosine kinase c-Met and vascular endothelial growth factor (VEGF) receptor tyrosine kinase. These compounds are stated to have wide therapeutic applications for the treatment of a variety of cancers, hypertension, arteriosclerosis, myocardial infarction and rheumatoid arthritis.

Keywords::

• angiogenesis
• c-Met
• hepatocyte growth factor (HGF)
• hepatocyte growth factor receptor (HGFR)
• invasion
• kinase insert domain containing receptor (KDR)
• lymphocyte-specific protein tyrosine kinase (Lck)
• metastasis
• proliferation
• receptor tyrosine kinase (RTK)
• scatter factor (SF)
• vascular endothelial growth factor (VEGF) receptor

Patent Details

• Title Compounds and methods of use

• Assignee Amgen, Inc.

• Inventors Harmange J, Booker S, Bauer D et al.

• Priority date 23/01/2004

• Filing date 24/01/2005

• Publication date 11/08/2005

• Publication no. WO2005073224